Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Autolus Therapeutics (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company focused on programmed T cell therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Dr. Christian Itin, will engage in a Fireside Chat scheduled for Wednesday, April 9, 2025, at 9:30am EDT / 14:30pm BST. The presentation will be accessible via webcast on the company's website under the 'Events' page in the 'Investor Relations & Media' section. Interested parties can access the replay for 90 days following the presentation.
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica in fase commerciale iniziale focalizzata sulle terapie con cellule T programmate, ha annunciato la sua partecipazione alla 24ª Conferenza Sanitaria Virtuale Annuale di Needham.
Il CEO dell'azienda, Dr. Christian Itin, parteciperà a una chiacchierata informale programmata per mercoledì 9 aprile 2025, alle 9:30 EDT / 14:30 BST. La presentazione sarà accessibile tramite webcast sul sito web dell'azienda nella pagina 'Eventi' nella sezione 'Relazioni con gli Investitori e Media'. Le parti interessate possono accedere alla registrazione per 90 giorni dopo la presentazione.
Autolus Therapeutics (Nasdaq: AUTL), una empresa biofarmacéutica en etapa comercial temprana centrada en terapias con células T programadas, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
El CEO de la empresa, Dr. Christian Itin, participará en una charla informal programada para miércoles 9 de abril de 2025, a las 9:30 a.m. EDT / 14:30 p.m. BST. La presentación será accesible a través de un webcast en el sitio web de la empresa en la página 'Eventos' en la sección 'Relaciones con Inversores y Medios'. Las partes interesadas pueden acceder a la repetición durante 90 días después de la presentación.
Autolus Therapeutics (Nasdaq: AUTL)는 프로그램된 T 세포 치료에 중점을 둔 초기 상업 단계의 생명공학 회사로, 제24회 연례 니드햄 가상 의료 회의에 참여한다고 발표했습니다.
회사의 CEO인 Dr. Christian Itin은 2025년 4월 9일 수요일, 오전 9시 30분 EDT / 오후 2시 30분 BST에 예정된 파이어사이드 챗에 참여할 예정입니다. 발표는 회사 웹사이트의 '이벤트' 페이지의 '투자자 관계 및 미디어' 섹션에서 웹캐스트를 통해 접근할 수 있습니다. 관심 있는 분들은 발표 후 90일 동안 재생을 이용할 수 있습니다.
Autolus Therapeutics (Nasdaq: AUTL), une entreprise biopharmaceutique en phase commerciale précoce axée sur les thérapies par cellules T programmées, a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Santé de Needham.
Le PDG de l'entreprise, Dr. Christian Itin, participera à une discussion informelle prévue pour mercredi 9 avril 2025, à 9h30 EDT / 14h30 BST. La présentation sera accessible par webcast sur le site de l'entreprise dans la page 'Événements' de la section 'Relations Investisseurs & Médias'. Les parties intéressées peuvent accéder à la rediffusion pendant 90 jours après la présentation.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen in der frühen Kommerzialisierungsphase, das sich auf programmierte T-Zell-Therapien konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt.
Der CEO des Unternehmens, Dr. Christian Itin, wird an einem Fireside Chat teilnehmen, der für Mittwoch, den 9. April 2025, um 9:30 Uhr EDT / 14:30 Uhr BST geplant ist. Die Präsentation wird über einen Webcast auf der Unternehmenswebsite unter der Seite 'Veranstaltungen' im Abschnitt 'Investor Relations & Media' zugänglich sein. Interessierte Parteien können die Wiederholung 90 Tage nach der Präsentation abrufen.
- None.
- None.
LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference.
Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST.
A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
FAQ
When is Autolus Therapeutics (AUTL) presenting at the Needham Healthcare Conference 2025?
How long will the AUTL Needham Conference presentation replay be available?
Where can investors watch Autolus' (AUTL) Needham Conference presentation?
What type of presentation will AUTL deliver at the 2025 Needham Healthcare Conference?
